Treatment of orbital pseudotumors and lymphoma

H. J. Barthold, A. Harvey, Arnold Markoe, L. W. Brady, J. J. Augsburger, J. A. Shields

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Thirty-seven patients were identified in a retrospective review at Hahnemann University and Wills Eye Hospital; they had been treated for pseudotumor or lymphoma of the orbit and had adequate follow-up (x = 61.5 months). Overall, 31 of 37 patients (83.8%) were cleared of their orbital disease. Of the nine patients treated for lymphoma, all were cleared of disease in the orbit. Twenty-two of 28 patients (78.6%) with benign disease were likewise cleared of orbital disease. Ten of 10 patients who received radiation as their initial therapy were cleared. Overall, 17 of 20 (85%) of patients who received radiation as part of their therapy were cleared of orbital disease, with mean dosages of 2,166 cGy (1cGy = 1 rad) for benign disease and 3,547 cGy for lymphoma. Brief representative case studies and a review of the literature are presented. Two patients with benign disease were cured of disease in the orbit but went on to develop systemic lymphoma. Radiation therapy plays an essential role in the management of patients with orbital lymphomatous diseases.

Original languageEnglish
Pages (from-to)527-532
Number of pages6
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume9
Issue number6
StatePublished - Dec 1 1986
Externally publishedYes

Fingerprint

Orbital Pseudotumor
Orbital Diseases
Lymphoma
Orbit
Therapeutics
Radiation
Orbital lymphoma
Radiotherapy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Barthold, H. J., Harvey, A., Markoe, A., Brady, L. W., Augsburger, J. J., & Shields, J. A. (1986). Treatment of orbital pseudotumors and lymphoma. American Journal of Clinical Oncology: Cancer Clinical Trials, 9(6), 527-532.

Treatment of orbital pseudotumors and lymphoma. / Barthold, H. J.; Harvey, A.; Markoe, Arnold; Brady, L. W.; Augsburger, J. J.; Shields, J. A.

In: American Journal of Clinical Oncology: Cancer Clinical Trials, Vol. 9, No. 6, 01.12.1986, p. 527-532.

Research output: Contribution to journalArticle

Barthold, HJ, Harvey, A, Markoe, A, Brady, LW, Augsburger, JJ & Shields, JA 1986, 'Treatment of orbital pseudotumors and lymphoma', American Journal of Clinical Oncology: Cancer Clinical Trials, vol. 9, no. 6, pp. 527-532.
Barthold HJ, Harvey A, Markoe A, Brady LW, Augsburger JJ, Shields JA. Treatment of orbital pseudotumors and lymphoma. American Journal of Clinical Oncology: Cancer Clinical Trials. 1986 Dec 1;9(6):527-532.
Barthold, H. J. ; Harvey, A. ; Markoe, Arnold ; Brady, L. W. ; Augsburger, J. J. ; Shields, J. A. / Treatment of orbital pseudotumors and lymphoma. In: American Journal of Clinical Oncology: Cancer Clinical Trials. 1986 ; Vol. 9, No. 6. pp. 527-532.
@article{07c6d7a4ea2142b2ba0207a90030d014,
title = "Treatment of orbital pseudotumors and lymphoma",
abstract = "Thirty-seven patients were identified in a retrospective review at Hahnemann University and Wills Eye Hospital; they had been treated for pseudotumor or lymphoma of the orbit and had adequate follow-up (x = 61.5 months). Overall, 31 of 37 patients (83.8{\%}) were cleared of their orbital disease. Of the nine patients treated for lymphoma, all were cleared of disease in the orbit. Twenty-two of 28 patients (78.6{\%}) with benign disease were likewise cleared of orbital disease. Ten of 10 patients who received radiation as their initial therapy were cleared. Overall, 17 of 20 (85{\%}) of patients who received radiation as part of their therapy were cleared of orbital disease, with mean dosages of 2,166 cGy (1cGy = 1 rad) for benign disease and 3,547 cGy for lymphoma. Brief representative case studies and a review of the literature are presented. Two patients with benign disease were cured of disease in the orbit but went on to develop systemic lymphoma. Radiation therapy plays an essential role in the management of patients with orbital lymphomatous diseases.",
author = "Barthold, {H. J.} and A. Harvey and Arnold Markoe and Brady, {L. W.} and Augsburger, {J. J.} and Shields, {J. A.}",
year = "1986",
month = "12",
day = "1",
language = "English",
volume = "9",
pages = "527--532",
journal = "American Journal of Clinical Oncology",
issn = "0277-3732",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Treatment of orbital pseudotumors and lymphoma

AU - Barthold, H. J.

AU - Harvey, A.

AU - Markoe, Arnold

AU - Brady, L. W.

AU - Augsburger, J. J.

AU - Shields, J. A.

PY - 1986/12/1

Y1 - 1986/12/1

N2 - Thirty-seven patients were identified in a retrospective review at Hahnemann University and Wills Eye Hospital; they had been treated for pseudotumor or lymphoma of the orbit and had adequate follow-up (x = 61.5 months). Overall, 31 of 37 patients (83.8%) were cleared of their orbital disease. Of the nine patients treated for lymphoma, all were cleared of disease in the orbit. Twenty-two of 28 patients (78.6%) with benign disease were likewise cleared of orbital disease. Ten of 10 patients who received radiation as their initial therapy were cleared. Overall, 17 of 20 (85%) of patients who received radiation as part of their therapy were cleared of orbital disease, with mean dosages of 2,166 cGy (1cGy = 1 rad) for benign disease and 3,547 cGy for lymphoma. Brief representative case studies and a review of the literature are presented. Two patients with benign disease were cured of disease in the orbit but went on to develop systemic lymphoma. Radiation therapy plays an essential role in the management of patients with orbital lymphomatous diseases.

AB - Thirty-seven patients were identified in a retrospective review at Hahnemann University and Wills Eye Hospital; they had been treated for pseudotumor or lymphoma of the orbit and had adequate follow-up (x = 61.5 months). Overall, 31 of 37 patients (83.8%) were cleared of their orbital disease. Of the nine patients treated for lymphoma, all were cleared of disease in the orbit. Twenty-two of 28 patients (78.6%) with benign disease were likewise cleared of orbital disease. Ten of 10 patients who received radiation as their initial therapy were cleared. Overall, 17 of 20 (85%) of patients who received radiation as part of their therapy were cleared of orbital disease, with mean dosages of 2,166 cGy (1cGy = 1 rad) for benign disease and 3,547 cGy for lymphoma. Brief representative case studies and a review of the literature are presented. Two patients with benign disease were cured of disease in the orbit but went on to develop systemic lymphoma. Radiation therapy plays an essential role in the management of patients with orbital lymphomatous diseases.

UR - http://www.scopus.com/inward/record.url?scp=0023002738&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023002738&partnerID=8YFLogxK

M3 - Article

C2 - 3788856

AN - SCOPUS:0023002738

VL - 9

SP - 527

EP - 532

JO - American Journal of Clinical Oncology

JF - American Journal of Clinical Oncology

SN - 0277-3732

IS - 6

ER -